

Preparation of Acidic 5-Hydroxy-1,2,3-triazoles via the Cycloaddition of Aryl Azides with β -Ketoesters

Roberta Pacifico,[▽] Dario Destro,[▽] Malachi W. Gillick-Healy, Brian G. Kelly, and Mauro F. A. Adamo*



Cite This: *J. Org. Chem.* 2021, 86, 11354–11360



Read Online

ACCESS |



Metrics & More




Article Recommendations



Supporting Information

ABSTRACT: Herein, a high-yielding cycloaddition reaction of β -ketoesters and azides to provide 1,2,3-triazoles is described. The reactions employing 2-unsubstituted β -ketoesters were found to provide 5-methyl-1,2,3-triazoles, whereas 2-alkyl-substituted β -ketoesters provided 5-hydroxy-1,2,3-triazoles (shown to be relatively acidic) in high yields and as single regioisomers. Several novel compounds were reported and characterized including long-chain 5-hydroxy-1,2,3-triazoles potentially bioisosteric to hydroxamic acids.



INTRODUCTION

1,2,3-Triazoles are important scaffolds employed in medicinal chemistry,¹ catalysis,² materials science,³ and biology.⁴ The electronic and physicochemical properties of triazoles bear a close similarity to those of the amide functionality and therefore can be classified as amide bioisosteres.^{5,6} Copper-catalyzed alkyne–azide cycloaddition is the most accredited method to synthesize substituted 1,2,3-triazoles,^{7–11} while the less well-known reactions of malonates or β -ketoesters with aromatic azides have become attractive alternatives as they do not require metal catalysts to proceed (Figure 1).¹²

β -Ketoesters react quickly with mild bases, providing highly reactive enolates that have a myriad of reported applications in organic chemistry.^{13,14} Dimroth reported a cycloaddition of β -ketoesters and azides in 1902¹⁵ where ethyl acetoacetate reacted with azidobenzene in the presence of sodium ethoxide to provide 5-hydroxytriazoles in poor yields. This material was properly identified; however, it was not characterized beyond the physical constants and, notably, their remarkable acidity was overlooked. More recently, Wang and co-workers reported the cycloaddition of β -ketoesters and azides, via organo-catalysis, to yield 1,4-disubstituted 1,2,3-triazoles.¹⁶ Intrigued by these reports^{15,16} where the same reagents gave rise to different products under similar basic conditions, and in a continuation of our studies on the reactivity of azides and enolates (Figure 1),¹⁷ we decided to re-examine the cycloaddition of simple ketoesters and aromatic azides in the presence of organic bases.

RESULTS AND DISCUSSION

This work involved reacting a selection of pyridyl- or aryl-azides and β -ketoesters and showed that distinct triazole products could be obtained in high yields via a divergent reaction pathway that led to either disubstituted 1,2,3-triazoles or 5-hydroxy-1,2,3-triazoles depending upon the nature of the





Figure 1. Historical and novel approaches for the synthesis of 1,2,3-triazoles.

β -ketoester. These findings were subsequently exploited to prepare a family of 5-hydroxytriazoles, whose acidity has been shown to be even stronger ($pK_a = 4.20$ for **5a**) than those for

Received: April 2, 2021

Published: July 27, 2021



Table 1. Cycloaddition of β -Ketoester **1a** with Aryl Azides **2^a**


entry	keto ester	aryl azide	Py	product	catalyst	solvent	yield (%) ^b
1	1a	2a	4-pyridyl	3a		MeCN	80
2	1a	2b	3-pyridyl	3b		MeCN	72
3	1a	2c	2-pyridyl	3c		MeCN	0
4	1a	2c	2-pyridyl	3c	Cu(OTf) ₂ ·C ₆ H ₅ CH ₃	DMSO	50

^aReaction conditions are as follows: **1a** (1.2 equiv), **2a–c** (1 equiv), DBU (1.2 equiv), and solvent (0.2 M). ^bIsolated yield.


analogous compounds ($pK_a = 5.14–6.21$) reported by Sainas and co-workers.¹⁸ Our observation of the relatively strong acidity of 5-hydroxytriazoles has the potential to be applied toward hydroxamic acid bioisosteres (Figure 1).

Our investigation began with the cycloaddition reaction of pyridyl azides **2a–c** with ethyl acetoacetate **1a** in the presence of organic soluble bases, from which 1,8-diazabicyclo[5.4.0]-undec-7-ene (DBU) gave the best yield. The reactions of pyridyl azides **2a** and **2b** with **1a** furnished triazoles **3a** and **3b** in 80% and 72% isolated yields, respectively, whereas the reaction of pyridyl azide **2c**, bearing an *ortho*-nitrogen, showed no conversion to **3c** (Table 1).

Compound **3c**, however, was obtained in average yields (50%) when a copper trifluoromethanesulfonate toluene complex (Cu(OTf)₂·C₆H₅CH₃) in dimethyl sulfoxide (DMSO) was added to the reaction mixture. The reaction of **1a** and phenyl azide **4a** (Table 2, entry 1) gave the disubstituted triazole ester **3d**¹⁶ in an excellent isolated yield. In summary, the reaction of unsubstituted **1a** with azides **2a–c** (Table 1) or **4a** (Table 2) under basic conditions provided 4,5-disubstituted 1,2,3-triazoles of a similar type to those reported by Wang.¹⁶ However, when 2-substituted β -ketoester **1b** was reacted with azide **4a** (Table 2, entry 2), a sharp diversion of


the reaction course was observed, and 5-hydroxy-triazole **5a** was isolated as the sole product (Table 2 entry 2). We then investigated the scope of the reaction, applying the same reaction protocol to β -ketoesters **1b** and **1c** and aryl azides (**4a–j**) (Table 2). Reactions of ketoester **1b** with aryl azides **4h–j** did not lead to the formation of any product, and only starting materials were recovered after 18 h. Reactions of ketoesters **1b** and **1c** with azides **4a–g** and **4a** under identical conditions provided 5-hydroxytriazoles **5a–g** and **5k**, which with the exception of **5a** are reported here for the first time. The chemical structure of **5a** was confirmed by single-crystal X-ray diffractometry (see Figure 2 and the Supporting Information).

The reaction of ketoesters **1b** and **1c** with aryl azides **4a–j** in the presence of 1.2 equiv of DBU in acetonitrile at 50 °C for 18 h provided 5-hydroxytriazoles **5a–k** in moderate to good yields. The reaction was, however, sensitive to the electronic effects of substituents of the azide, where electron-neutral azides **4a**, **4b**, **4d**, and **4e** gave highest yields. The electron-rich azide **4c** reacted well, albeit the yields were lower. Aromatic azides **4f–g** bearing strong electron-withdrawing groups provided the corresponding 5-hydroxytriazoles **5f–g** in only moderate yields. Steric hindrance from aryl substituents of aryl azides **4** was not found to affect reaction yield. The potential for the organo-catalytic activity of DBU in this reaction was also investigated; however, no evidence to support this was found. We then proceeded to optimize the reaction conditions between **1b** and **4a** by varying the base, solvent, temperature, and reaction times.


Table 2. Cycloaddition of β -Ketoesters and Aryl Azides to Give 5-Hydroxytriazoles^a


entry	ketoester	R	aryl azide	Ar	product	time (h)	yield (%) ^b
1	1a	H	4a	Ph	3d	18	87
2	1b	Me	4a	Ph	5a	6	80
3	1b	Me	4a	Ph	5a	18	98 ^c
4	1b	Me	4b	4-BrC ₆ H ₄	5b	18	87
5	1b	Me	4c	4-OMeC ₆ H ₄	5c	18	62
6	1b	Me	4d	2-PhC ₆ H ₄	5d	18	75
7	1b	Me	4e	1-naphthyl	5e	18	79
8	1b	Me	4f	4-NO ₂ C ₆ H ₄	5f	18	53
9	1b	Me	4g	2-NO ₂ -4-MeC ₆ H ₃	5g	18	56
10	1b	Me	4h	2-Br-C ₆ H ₄	5h	18	n.r. ^d
11	1b	Me	4i	<i>n</i> -Bu	5i	18	n.r. ^d
12	1b	Me	4j	Bn	5j	18	n.r. ^d
13	1c	Bn	4a	Ph	5k	18	75

^aReaction conditions are as follows: **1b** or **1c** (1.2 equiv), **4a–j** (1 equiv), and DBU (1.2 equiv) in MeCN (0.2 M) at 50 °C. ^bIsolated yield. ^c¹H-NMR spectroscopic yield. ^dNo reaction.

Figure 2. X-ray crystal structure of 5-hydroxytriazole **5a**.²⁷


The high yield obtained when reacting **1b** with **4a** in the presence of solid KOH (potassium hydroxide) as a base and TBAB (tetrabutylammonium bromide) as a PTC (phase-transfer catalyst) encouraged us to study the scope of this transformation (Table 3). Phase-transfer conditions were found to be particularly effective with electron-poor and electron-neutral azides, such as **4a**, **4g**, and **4h**, with yields up to 95%. However, when bulky azide substituents were present, such as **4e**, only the hydrolyzed product **6** was favored over cyclization (Table 3). Since compound **5a**

Table 3. Synthesis of 5-Hydroxytriazoles: PTC-Mediated Cycloaddition of β -Ketoester **1b and Aryl Azides **4**^a**

entry	aryl azide	Ar	product	time (h)	yield (%) ^b
1	4a	Ph	5a	4	95
2	4e	1-naphthyl	5e	18	n.r. ^c
3	4g	4-NO ₂ C ₆ H ₄	5f	4	76
4	4h	2-NO ₂ -4-MeC ₆ H ₃	5g	4	83

^aReaction conditions are as follows: **1b** (1.2 equiv), **4** (1.2 equiv), TBAB (0.1 equiv), and KOH (2.2 equiv) in Et₂O (0.2 M) at 20 °C. ^bIsolated yield. ^cOnly the hydrolysis product 2-methyl-3-oxobutanoic acid (**6**) was formed.


behaved as a relatively strong Brønsted acid, we decided to carry out a titration experiment to better characterize its properties. The pK_a of **5a** was found to be 4.2, which is comparable to that of a carboxylic acid (see the Supporting Information).¹⁹ This result was very unexpected compared to the pK_a values of the related 4-hydroxy-1,2,3-triazoles, which were found to be significantly less acidic than those reported by Pippione and co-workers.²⁰ Moreover, we found 5-hydroxytriazoles to be highly soluble in water when accompanied by both organic and inorganic bases, thus justifying their attractiveness as candidates for drug discovery. We further expanded the scope of the cyclization reaction to include cyclic β -ketoesters **7a–c** to provide novel long-chain 5-hydroxytriazoles **8**. Interestingly, poor conversion was observed when the reaction was performed in solvent, while we saw a notable improvement when the cyclization was performed solvent-free with yields up to 79% (Table 4).

Table 4. Synthesis of Long-Chain 5-Hydroxytriazoles^a

entry	ketoester	R	n	solvent	product	yield (%) ^b
1	7a	Et	1	MeCN	8a	29
2	7a	Et	1	none	8a	44
3	7b	Me	2	none	8b	79
4	7c	Et	3	none	8c	38


^aReaction conditions are as follows: **7** (1.2 equiv), **4a** (1 equiv), and DBU (1.2 equiv) at 50 °C for 18 h. ^bIsolated yield.

A literature search highlighted the structural similarity of 5-hydroxytriazoles and hydroxamic acids.²¹ Hydroxamic acids and 5-hydroxytriazoles share similar pK_a values and amide-like bioisosterism, which makes them excellent ligands for enzyme-bound metals. Compounds **5a–g** and **8** reacted with Fe²⁺ and Cu²⁺ salts to provide blue-violet and red-colored solutions, indicating a ligand-like behavior similar to that of hydroxamic acids. Suberanolhydroxamic acid **9** (SAHA) is a hydroxamic acid that is active as a histone deacetylase (HDAC) inhibitor.^{22,23} To exemplify the potential of the 5-hydroxytriazole nucleus in medicinal chemistry, we set out to convert long-chain 5-hydroxytriazoles **8a–c** into terminal *N*-phenylamide-substituted triazoles **10a–c**, which bear a close structural relationship to hydroxamic acid **9** (Figure 3).

**Figure 3. Structural similarities between HDAC inhibitor SAHA (**9**) and long-chain 5-hydroxytriazoles (**10a–c**).**

The preparation of **10a–c** ($n = 1–3$, respectively) is reported in the Experimental section. The structural and functional similarities between hydroxamic acid **9** and 5-hydroxytriazoles **10** are highlighted in Figure 3 and include the following: (i) nominally similar scaffolds and chemical functionalities; (ii) analogous lone pairs (circled in red) of the carbonyl oxygen of the hydroxamic acid and the pyridyl-like N of the triazole system;²⁴ (iii) hydrophobic backbones (circled in green), which are essential for interaction with active sites of HDAC isoforms, e.g., zinc-binding groups; and (iv) aromatic rings (in pink), which are essential for the correct positioning in the enzyme active site via π – π stacking.²⁵

Based on the reactivity observed, two reaction mechanisms have been proposed (Scheme 1), which lead to distinct

Scheme 1. Proposed Distinct Mechanistic Pathways for the Formation of 5-Hydroxytriazoles **5 (Pathway a) versus 5-Methyl-triazoles **3** (Pathway b)**

products via analogous intermediates **12a** and **12b**. Intermediates **12a** and **12b** arise from reaction of enolate **11** with aryl azides (pathway a or pathway b), respectively. In pathway a, species **12a** is formed and will evolve toward cyclic amide **13a**, which contains no enolizable proton, and the concomitant elimination of ethoxide. A subsequent attack of ethoxide to the acetoxy group in **13a** will lead to the elimination of ethyl acetate and the formation of **5**. Conversely, in the presence of an enolizable proton such as in **12b** (pathway b), the following cyclization to **13b** and its subsequent protonation will generate **14b**, which will provide compounds **3** after dehydration. A rationale similar to ours used to explain the mechanism in Scheme 1 has been reported by Pedersen and Begtrup for the reaction between phenyl azides and amides of malonic acids.²⁶

CONCLUSION

In conclusion, we have demonstrated that aryl azides undergo two distinct cycloaddition reactions with enolizable β -ketoesters depending on the substitution pattern on the β -ketoester, leading to different products. The cycloaddition of 2-unsubstituted β -ketoester with pyridyl azides and phenyl azide was found to lead to 5-methyl-triazoles, whereas the cycloaddition of 2-alkyl-substituted β -ketoesters with phenyl azide and substituted aryl azides was found to lead to 5-hydroxytriazoles, where the structure of one of the products has been confirmed via X-ray diffractometry (see Figure 2 and the Supporting Information).²⁷ The reaction of phenyl azide and substituted aryl azides with 2-alkyl-substituted β -ketoesters has been shown to be a fast, mild, and high-yielding method for the synthesis of 5-hydroxy-1,2,3-triazoles. The relatively acidic nature we observed for the 5-hydroxytriazoles has led us propose the study of 5-hydroxytriazole analogues as a new class of bioisosteres of hydroxamic acids. Future work will involve an investigation of this novel class of compounds as potential biological targets and their potential as a bioisosteric relative of biologically active hydroxamic acids.

EXPERIMENTAL SECTION

¹H and ¹³C{¹H} NMR spectra were recorded on a Bruker 400 spectrometer. Chemical shifts (δ) are reported in parts per million (ppm) relative to residual solvent signals (¹H NMR, 7.26 ppm for CDCl₃, 2.50 ppm for DMSO-*d*₆, and 3.31 ppm for CD₃OD; ¹³C{¹H} NMR, 77.16 ppm for CDCl₃, 39.53 ppm for DMSO-*d*₆, and 49.03 for CD₃OD). ¹³C{¹H} NMR spectra were acquired with the ¹H broad band decoupled mode. Coupling constants (*J*) are in hertz (Hz). Melting points were measured using a Stuart scientific melting point apparatus and were uncorrected. Infrared spectra (IR) were recorded with KBr discs using a Bruker Tensor27 FT-IR instrument. High-resolution mass spectra were obtained on a Waters Micromass GCT PremierMS spectrometer or on a Bruker microTOF-Q III LC-MS spectrometer (APCI method). Optical rotations were measured on a PerkinElmer 343 polarimeter. HPLC chromatograms was recorded on a YMC-Triart Phenyl 150 × 4.6 mm column using a 5 μ L injection volume (60:40 MeCN/H₂O) at two different wavelengths of 190 and 254 nm, respectively. The purity of the final products was verified by HPLC analysis and ¹H and ¹³C{¹H} NMR spectroscopy. Analytical-grade solvents and commercially available reagents were used as received. Dry DCM was purchased from Sigma-Aldrich. Reactions were monitored by TLC (Merck, silica gel 60 F254). Flash column chromatography was performed using silica gel 60 (0.040–0.063 mm, 230–400 mesh). Substituted arylazides 4a–j²⁸ and pyridyl azides 2a–c were prepared according to reported procedures.^{29,30} β -Ketoesters 1a–c and modified ketoesters 7a–c were purchased from Sigma-Aldrich and used without further purification. 5-Hydroxy-1,2,3-triazoles 5a, 5e, 5f, and 5g were synthesized via phase-transfer catalysis according to GP3 and via DBU-promoted synthesis according to GP2, while 5-hydroxy-1,2,3-triazoles 5b, 5c, 5d, and 5k were synthesized according to GP2 via a DBU-promoted synthesis. 5-Methyl-1,2,3-triazoles 3a–b were synthesized according to the GP1 procedure. 5-Methyl-1,2,3-triazole 3c was synthesized according to a modified version of GP1. Long-chained 5-hydroxy-1,2,3-triazoles based SAHA analogs 10b–c were synthesized according to GP6 via long-chained 5-hydroxy-1,2,3-triazole precursors 8a–c, which were synthesized according to GP4. The long-chained 5-hydroxy-1,2,3-triazole-based SAHA analog 10a was synthesized according to a modified version of GP4.

General Procedure for the DBU-Promoted Synthesis of 5-Methyl-1,2,3-triazoles 3a and 3b (GP1). To a solution of pyridyl azides 2a or 2b (0.5 mmol, 1 equiv) and β -ketoester 1a (0.6 mmol, 1.2 equiv) in MeCN (2.5 mL, 0.2M) was added DBU (0.6 mmol, 1.2 equiv), and the reaction mixture was stirred at 50 °C in an oil bath overnight. The crude mixture was evaporated under vacuum and

purified via flash column chromatography (MeOH/DCM/AcOH 90:10:0.1) to afford title compounds 3a and 3b as solids.

Ethyl 5-Methyl-1-(pyridin-4-yl)-1H-1,2,3-triazole-4-carboxylate 3a. Yellow solid (93 mg, 80% yield). ¹H NMR (400 MHz, CDCl₃): δ 8.88 (d, *J* = 6.1 Hz, 2H), 7.51 (d, *J* = 6.1 Hz, 2H), 4.48 (q, *J* = 7.1 Hz, 2H), 2.72 (s, 3H), 1.46 (t, *J* = 7.1 Hz, 3H). ¹³C{¹H} NMR (101 MHz, CDCl₃): δ 161.4, 151.7, 142.5, 138.7, 118.7, 61.4, 14.4, 10.3. IR (KBr, cm⁻¹): 3278, 3132, 3100, 1748, 1560, 1480. mp 120–120.7 °C. HRMS (ESI) *m/z*: [M + H]⁺ calcd for C₁₁H₁₂N₄O₂ 232.0960, found 232.0948.

Ethyl 5-Methyl-1-(pyridin-3-yl)-1H-1,2,3-triazole-4-carboxylate 3b. Yellow solid (84 mg, 72% yield). ¹H NMR (400 MHz, CDCl₃): δ 8.83 (d, *J* = 4.8 Hz, 1H), 8.78 (s, 1H), 7.89 (d, *J* = 8.1 Hz, 1H), 7.58 (dd, *J* = 8.1, 4.8 Hz, 1H), 4.48 (q, *J* = 7.1 Hz, 2H), 2.65 (s, 3H), 1.46 (t, *J* = 7.1 Hz, 3H). ¹³C{¹H} NMR (101 MHz, CDCl₃): δ 161.5, 151.2, 145.9, 139.1, 137.2, 132.9, 132.4, 124.3, 77.1, 77.1, 76.8, 61.3, 14.4, 9.9. All analytical data are consistent with those reported in the literature.³¹

Synthesis of Ethyl 5-Methyl-1-(pyridin-2-yl)-1H-1,2,3-triazole-4-carboxylate 3c. To a solution of 2c (100 mg, 0.83 mmol, 1 equiv) in DMSO (1.4 mL, 0.6M) were added 1a (141 μ L, 1 mmol, 1.2 equiv), DBU (150 μ L, 1 mmol, 1.2 equiv), and Cu(OTf)₂·C₆H₅CH₃ (43 mg, 0.083 mmol, 0.1 equiv). The reaction mixture turned from light brown to black upon the addition of the catalyst and was stirred for 8 h at reflux in an oil bath. After 8 h, TLC showed the complete consumption of 2c, and the mix was cooled to room temperature and extracted with DCM/H₂O three times. The collected organic phases were filtered through a Celite pad and concentrated in vacuo. The crude product was purified by flash column chromatography (DCM/AcOEt 90:10) to afford the product 3c in a modest yield (58 mg, 50% yield) as a yellow oil. TLC showed the product to be visible as a brilliant purple spot under an UV lamp at a short wavelength. All analytical data are consistent with those reported in the literature. ¹H NMR (400 MHz, CDCl₃): δ 8.58 (d, *J* = 4.6 Hz, 1H), 7.95 (m, 2H), 7.42 (m, 1H), 4.46 (q, *J* = 7.1 Hz, 2H), 2.91 (s, 3H), 1.44 (t, *J* = 7.1 Hz, 3H). ¹³C{¹H} NMR (101 MHz, CDCl₃): δ 160.7, 149.2, 147.5, 138.7, 138.1, 136.3, 123.1, 117.34, 60.1, 13.4, 10.0.

General Procedure for the DBU-Promoted Synthesis of 5-Hydroxy-1,2,3-triazoles 5a–k (GP2). To a solution of aryl azides 4 (0.5 mmol, 1 equiv) and β -ketoester 1 (0.6 mmol, 1.2 equiv) in MeCN (0.2M) was added DBU (0.6 mmol, 1.2 equiv), and the reaction mixture was stirred at 50 °C in an oil bath overnight. The crude mixture was evaporated under vacuum and purified via flash column chromatography (MeOH/DCM/AcOH 90:10:0.1) to afford title compounds 5a–k as solids. In some cases after chromatography, products 5a–k still contained traces of the DBU salt, which were easily removed by the trituration of the solid with a minimum quantity of water.

General Procedure for the Synthesis of 5-Hydroxy-1,2,3-triazoles 5a and 5e–g via Phase-Transfer Catalysis (GP3). To a solution of aryl azides 4a, 4e–g (1.2 mmol, 1 equiv), and β -ketoester 1 (1.2 mmol, 1 equiv) in diethyl ether (0.2M) were added tetrabutylammonium bromide (0.11 mmol, 10 mol %) and finely ground KOH (2.4 mmol, 2 equiv) at room temperature. After 4 h of vigorous stirring, the white precipitate was collected by vacuum filtration. The solid, a potassium salt of 5, was dispersed in 1 mL of MeCN, and acetic acid was added until dissolution. The mixture was evaporated and purified via flash column chromatography (MeOH/DCM 1:9) to afford the products 5a and 5e–g.

5-Hydroxy-4-methyl-1-phenyl-1,2,3-triazole 5a. Prepared according both GP2 and GP3 to provide 5a as a white solid (70 mg, 80% yield and 201 mg, 95% yield, respectively). ¹H NMR (400 MHz, CDCl₃): δ 12.82 (bs, 1H), 7.80 (d, *J* = 7.7 Hz, 2H), 7.44 (t, *J* = 7.7 Hz, 2H), 7.39 (t, *J* = 7.4 Hz, 1H), 2.25 (s, 3H). ¹³C{¹H} NMR (101 MHz, CDCl₃): δ 152.2, 135.8, 129.1, 128.4, 122.4, 119.6, 8.3. IR (KBr, cm⁻¹): 1852, 1493, 759. mp 140–140.1 °C. HRMS (ESI) *m/z*: [M + H]⁺ calcd for C₉H₁₀N₃O 176.0824, found 176.0819.

5-Hydroxy-4-methyl-1-(4-bromophenyl)-1,2,3-triazole 5b. Prepared according to GP₂. Off-white solid (110 mg, 87% yield). ¹H NMR (400 MHz, DMSO-*d*₆): δ 11.76 (bs, 1H), 7.70–7.74 (m, 4H),

2.18 (s, 3H). $^{13}\text{C}\{^1\text{H}\}$ NMR (101 MHz, DMSO- d_6): δ 147.2, 135.5, 132.8, 124.2, 123.2, 121.0, 9.6. IR (KBr, cm^{-1}): 2389, 1991, 1493. mp 154–154.4 °C. HRMS (ESI) m/z : $[\text{M} + \text{H}]^+$ calcd for $\text{C}_9\text{H}_9\text{BrN}_3\text{O}$ 253.9929, found 253.9935.

5-Hydroxy-4-methyl-1-(4-methoxyphenyl)-1,2,3-triazole 5c. Prepared according to GP₂. White solid (64 mg, 62% yield). ^1H NMR (400 MHz, DMSO- d_6): δ 9.67 (bs, 1H), 7.57 (d, $J = 9.0$ Hz, 1H), 7.09 (d, $J = 9.0$ Hz, 1H), 3.82 (s, 1H), 2.17 (s, 1H). $^{13}\text{C}\{^1\text{H}\}$ NMR (101 MHz, DMSO- d_6): δ 159.3, 146.8, 129.2, 124.5, 123.2, 114.9, 55.9, 9.7. IR (KBr, cm^{-1}): 2616, 1522, 1257. mp 153–154 °C. HRMS (ESI) m/z : $[\text{M} + \text{H}]^+$ calcd for $\text{C}_{10}\text{H}_{12}\text{N}_3\text{O}_2$ 206.0930, found 206.0928.

5-Hydroxy-4-methyl-1-(2-phenylphenyl)-1,2,3-triazole 5d. Prepared according to GP₂. Off-white solid (95 mg, 75% yield). ^1H NMR (400 MHz, DMSO- d_6): δ 9.87 (bs, 1H), 7.70–7.62 (m, 1H), 7.61–7.52 (m, 2H), 7.49–7.41 (m, 1H), 7.36–7.25 (m, 3H), 7.18–7.05 (m, 2H), 2.05 (s, 3H). $^{13}\text{C}\{^1\text{H}\}$ NMR (101 MHz, DMSO- d_6): δ 158.9, 147.9, 139.2, 138.3, 133.1, 131.2, 130.7, 128.9, 128.8, 128.5, 127.9, 122.0, 9.6. IR (KBr, cm^{-1}): 2315, 1597, 1478, 1271, 1232. mp 143–143.7 °C. HRMS (ESI) m/z : $[\text{M} + \text{H}]^+$ calcd for $\text{C}_{15}\text{H}_{14}\text{N}_3\text{O}$ 252.1137, found 252.1129.

5-Hydroxy-4-methyl-1-(1-naphthyl)-1,2,3-triazole 5e. Prepared according to GP₂. White solid (89 mg, 79% yield). ^1H NMR (400 MHz, DMSO- d_6): δ 8.16 (d, $J = 8.2$ Hz, 1H), 8.10 (d, $J = 7.8$ Hz, 1H), 7.73–7.56 (m, 4H), 7.36 (d, $J = 8.2$ Hz, 1H), 2.28 (s, 3H). $^{13}\text{C}\{^1\text{H}\}$ NMR (101 MHz, DMSO- d_6): δ 148.3, 134.1, 131.9, 130.4, 129.4, 128.6, 128.0, 127.3, 125.9, 125.6, 123.1, 122.4, 9.8. IR (KBr, cm^{-1}): 3236, 2980, 2867, 2167. mp 119–119.3 °C. HRMS (ESI) m/z : $[\text{M} + \text{H}]^+$ calcd for $\text{C}_{13}\text{H}_{12}\text{N}_3\text{O}$ 226.0980, found 226.0972.

5-Hydroxy-4-methyl-1-(4-nitrophenyl)-1,2,3-triazole 5f. Prepared according to both GP₂ and GP₃. Yellow solid (59 mg, 53% yield and 202 mg, 76% yield, respectively). ^1H NMR (400 MHz, DMSO- d_6): δ 12.45 (bs, 1H), 8.42 (d, $J = 9.1$ Hz, 2H), 8.13 (d, $J = 9.1$ Hz, 2H), 2.19 (s, 3H). $^{13}\text{C}\{^1\text{H}\}$ NMR (101 MHz, DMSO- d_6): δ 146.3, 141.3, 125.6, 125.2, 121.9, 120.6, 9.51. IR (KBr, cm^{-1}): 3350, 2350, 1517, 1330. mp 156–157.2 °C. HRMS (ESI) m/z : $[\text{M} + \text{H}]^+$ calcd for $\text{C}_9\text{H}_9\text{N}_4\text{O}_3$ 221.0675, found 221.0679.

5-Hydroxy-4-methyl-1-(4-methyl-2-nitrophenyl)-1,2,3-triazole 5g. Prepared according to both GP₂ and GP₃. Yellow solid (66 mg, 56% yield and 234 mg, 83% yield, respectively). ^1H NMR (400 MHz, CD₃OD): δ 8.00 (s, 1H), 7.71 (d, $J = 8.0$ Hz, 1H), 7.57 (d, $J = 8.0$ Hz, 1H), 2.54 (s, 3H), 2.22 (s, 3H). $^{13}\text{C}\{^1\text{H}\}$ NMR (101 MHz, CD₃OD): δ 145.8, 143.4, 137.0, 135.7, 129.6, 126.7, 126.6, 123.9, 21.0, 8.4. IR (KBr, cm^{-1}): 3088, 2921, 1183, 759. mp 112–112.9 °C. HRMS (ESI) m/z : $[\text{M} + \text{H}]^+$ calcd for $\text{C}_{10}\text{H}_{11}\text{N}_4\text{O}_3$ 235.0831, found 235.0822.

5-Hydroxy-4-benzyl-1-phenyl-1,2,3-triazole 5k. Prepared according to GP₂. White solid (95 mg, 75% yield). ^1H NMR (400 MHz, DMSO- d_6): δ 12.30 (bs, 1H), 7.75 (d, $J = 7.5$ Hz, 2H), 7.57–7.50 (m, 2H), 7.46–7.40 (m, 1H), 7.29–7.24 (m, 4H), 7.22–7.15 (m, 1H), 3.96 (s, 2H). $^{13}\text{C}\{^1\text{H}\}$ NMR (101 MHz, DMSO- d_6): δ 147.5, 140.2, 136.0, 129.3, 128.3, 128.2, 127.7, 126.2, 125.9, 122.0, 29.3. IR (KBr, cm^{-1}): 2783, 1596, 1493. mp 146–146.5 °C. HRMS (ESI) m/z : $[\text{M} + \text{H}]^+$ calcd for $\text{C}_{15}\text{H}_{14}\text{N}_3\text{O}$ 252.1137, found 252.1130.

General Procedure for the Synthesis of Long-Chained 5-Hydroxy-1,2,3-triazole Esters 8a–c (GP4). To a mixture of commercially available cyclic ketoesters 7a–c (2.4 mmol, 1.2 equiv) and azidobenzene 4a (2.0 mmol, 1 equiv) in MeCN (0.2M) was added DBU (2.4 mmol, 1.2 equiv), and the reaction mixture was stirred at 60 °C in an oil bath overnight. The crude mixture was purified by silica flash chromatography (AcOEt/petroleum ether gradient from 1:2 to 1:0) to afford 1,2,3-triazole esters 8a–c as solids. Better yields were obtained when using the same protocol in solvent-free conditions.

Ethyl 5-(5-Hydroxy-1-phenyl-1,2,3-triazol-4-yl)pentanoic Ester 8a. Off-white solid (153 mg, 44% yield in solvent-free conditions versus 101 mg, 29% yield with solvent present). ^1H NMR (400 MHz, CDCl₃): δ 13.50 (bs, 1H), 7.85 (d, $J = 7.7$ Hz, 2H), 7.46 (t, $J = 6.9$ Hz, 2H), 7.36 (t, $J = 7.4$ Hz, 1H), 4.06 (q, $J = 7.2$ Hz, 2H), 2.70 (t, $J = 7.1$ Hz, 2H), 2.24 (t, $J = 7.2$ Hz, 2H), 1.75–1.53 (m, 4H), 1.19 (t, $J =$

7.1 Hz, 3H). $^{13}\text{C}\{^1\text{H}\}$ NMR (101 MHz, CDCl₃): δ 173.9, 152.0, 135.7, 129.1, 128.4, 123.3, 122.4, 60.4, 33.8, 27.8, 24.1, 22.4, 14.2. IR (KBr, cm^{-1}): 2507, 1734, 1604, 1570. mp 98–99.1 °C. HRMS (ESI) m/z : $[\text{M} + \text{H}]^+$ calcd for $\text{C}_{15}\text{H}_{20}\text{N}_3\text{O}_3$ 290.1505, found 290.1502.

Methyl 6-(5-Hydroxy-1-phenyl-1,2,3-triazol-4-yl)hexanoic Ester 8b. Off-white solid (275 mg, 79% yield in solvent-free conditions). ^1H NMR (400 MHz, CDCl₃): δ 10.61 (bs, 1H), 7.87 (d, $J = 7.7$ Hz, 2H), 7.49–7.40 (m, 2H), 7.38–7.33 (m, 1H), 3.61 (s, 3H), 2.65 (t, $J = 7.6$ Hz, 2H), 2.22 (t, $J = 7.4$ Hz, 2H), 1.69–1.61 (m, 2H), 1.60–1.51 (m, 2H), 1.34–1.24 (m, 2H). $^{13}\text{C}\{^1\text{H}\}$ NMR (101 MHz, CDCl₃): δ 174.5, 151.5, 136.0, 129.0, 128.2, 124.3, 122.2, 51.6, 33.8, 28.5, 28.2, 24.3, 22.7. IR (KBr, cm^{-1}): 2857, 2512, 1744, 1606. mp 112–112.6 °C. HRMS (ESI) m/z : $[\text{M} + \text{H}]^+$ calcd for $\text{C}_{15}\text{H}_{20}\text{N}_3\text{O}_3$ 290.1505, found 290.1492.

Ethyl 7-(5-Hydroxy-1-phenyl-1,2,3-triazol-4-yl)heptanoic ester 8c. Off-white solid (145 mg, 38% yield in solvent-free conditions). ^1H NMR (400 MHz, CDCl₃): δ 13.43 (bs, 1H), 7.90 (d, $J = 7.6$ Hz, 2H), 7.50–7.42 (m, 2H), 7.40–7.32 (m, 1H), 4.08 (q, $J = 7.1$ Hz, 2H), 2.64 (t, $J = 7.6$ Hz, 2H), 2.18 (t, $J = 7.5$ Hz, 2H), 1.71–1.58 (m, 2H), 1.55–1.45 (m, 2H), 1.33–1.10 (m, 7H). $^{13}\text{C}\{^1\text{H}\}$ NMR (101 MHz, CDCl₃): δ 174.0, 151.9, 136.1, 129.0, 128.1, 124.1, 122.2, 60.3, 34.2, 28.8, 28.7, 28.5, 24.8, 23.0, 14.2. IR (KBr, cm^{-1}): 2869, 2524, 1732, 1599. mp 100–101.3 °C. HRMS (ESI) m/z : $[\text{M} + \text{H}]^+$ calcd for $\text{C}_{17}\text{H}_{24}\text{N}_3\text{O}_3$ 318.1818, found 318.1816.

General Procedure for the Synthesis of Long-Chained 5-Hydroxy-1,2,3-triazolecarboxylic acids 11a–c (GP5). To a dispersion of 1,2,3-triazole esters 8a–c (0.5 mmol, 1 equiv) in water (0.1M) at 0 °C was added KOH pellets (5.0 mmol, 10 equiv). Upon the complete dissolution of KOH and the ester, the ice bath was removed, and the reaction mixture was vigorously stirred for 2 h at room temperature. The reaction mixture was again cooled to 0 °C, and HCl (37% aq.) was added dropwise to reach pH 1 and precipitate out the free form of the desired compound. The latter was collected by vacuum filtration and dried under vacuum to afford 5-hydroxy-1,2,3-triazolecarboxylic acids 11a–c in their pure form.

5-(5-Hydroxy-1-phenyl-1,2,3-triazol-4-yl)pentanoic Acid 11a. White solid (79 mg, 60% yield). ^1H NMR (400 MHz, DMSO- d_6): δ 11.95 (bs, 1H), 11.38 (bs, 1H), 7.65 (d, $J = 7.3$ Hz, 2H), 7.56–7.45 (m, 2H), 7.44–7.34 (m, 1H), 2.51 (t, $J = 6.8$ Hz, 2H), 2.19 (t, $J = 6.8$ Hz, 2H), 1.65–1.42 (m, 4H). $^{13}\text{C}\{^1\text{H}\}$ NMR (101 MHz, DMSO- d_6): δ 174.5, 135.8, 129.4, 128.0, 122.2, 33.5, 28.4, 24.2, 23.1. IR (KBr, cm^{-1}): 3340, 2350, 1700, 1601, 1562. mp 122–122.8 °C. HRMS (ESI) m/z : $[\text{M} + \text{H}]^+$ calcd for $\text{C}_{13}\text{H}_{16}\text{N}_3\text{O}_3$ 262.1192, found 262.1184.

6-(5-Hydroxy-1-phenyl-1,2,3-triazol-4-yl)hexanoic Acid 11b. White solid (122 mg, 88% yield). ^1H NMR (400 MHz, DMSO- d_6): δ 11.80 (s, 2H), 7.67 (d, $J = 7.8$ Hz, 2H), 7.53–7.46 (m, 2H), 7.44–7.36 (m, 1H), 2.51 (t, $J = 7.6$ Hz, 2H), 2.17 (t, $J = 7.4$ Hz, 2H), 1.61–1.44 (m, 4H), 1.35–1.23 (m, 2H). $^{13}\text{C}\{^1\text{H}\}$ NMR (101 MHz, DMSO- d_6): δ 174.6, 135.9, 129.3, 127.9, 122.2, 33.7, 28.6, 28.3, 24.4, 23.2. IR (KBr, cm^{-1}): 3395, 2938, 1724, 1629, 1599. mp 115–115.3 °C. HRMS (ESI) m/z : $[\text{M} + \text{H}]^+$ calcd for $\text{C}_{14}\text{H}_{18}\text{N}_3\text{O}_3$ 276.1348, found 276.1333.

7-(5-Hydroxy-1-phenyl-1,2,3-triazol-4-yl)heptanoic Acid 11c. White solid (118 mg, 81% yield). ^1H NMR (400 MHz, DMSO- d_6): δ 11.89 (bs, 2H), 7.71 (d, $J = 7.7$ Hz, 2H), 7.58–7.50 (m, 2H), 7.48–7.39 (m, 1H), 2.58–2.52 (m, 2H), 2.20 (t, $J = 7.3$ Hz, 2H), 1.63–1.54 (m, 2H), 1.54–1.44 (m, 2H), 1.38–1.27 (m, 4H). $^{13}\text{C}\{^1\text{H}\}$ NMR (101 MHz, DMSO- d_6): δ 174.6, 135.8, 129.3, 128.0, 122.2, 33.7, 28.7, 28.5, 28.4, 24.5, 23.3. IR (KBr, cm^{-1}): 3223, 2948, 1717, 1599. mp 117–117.4 °C. HRMS (ESI) m/z : $[\text{M} + \text{H}]^+$ calcd for $\text{C}_{15}\text{H}_{20}\text{N}_3\text{O}_3$ 290.1505, found 290.1518.

Synthesis of N-Phenyl-5-(5-hydroxy-1-phenyl-1,2,3-triazol-4-yl)pentanamide 10a. Carboxylic acid 11a (0.49 mmol, 1 equiv) was dissolved in thionyl chloride (0.49 M). The reaction mixture was refluxed at 60 °C for 2 h in an oil bath. The reaction mixture was evaporated under vacuum to remove the excess thionyl chloride. The crude acyl chloride was dissolved in dry DCM (1 mL), and to the solution were added aniline (0.54 mmol, 1.1 equiv) and triethylamine (0.54 mmol, 1.1 equiv). The reaction mixture was stirred at room

temperature under nitrogen overnight. The crude was diluted in AcOEt (20 mL) and washed with saturated sodium bicarbonate (5 mL) and HCl (5 mL of 1 M aq.). The organic phase was dried over sodium sulfate and evaporated under vacuum. The crude amide was purified by flash column chromatography (AcOEt/petroleum ether 1:1 to 1:0) to yield the target compound **10a** in a 61% yield (101 mg) as a white solid. $^1\text{H NMR}$ (400 MHz, DMSO- d_6): δ 9.80 (s, 1H), 7.72 (d, $J = 7.8$ Hz, 2H), 7.64–7.51 (m, 4H), 7.48–7.39 (m, 1H), 7.32–7.23 (m, 2H), 7.06–6.97 (m, 1H), 2.67–2.58 (m, 2H), 2.42–2.31 (m, 2H), 1.75–1.60 (m, 4H). $^{13}\text{C}\{^1\text{H}\}$ NMR (101 MHz, DMSO- d_6): δ 171.3, 139.4, 135.8, 129.3, 128.7, 128.0, 123.0, 122.2, 119.1, 36.4, 28.6, 24.9, 23.2. IR (KBr, cm^{-1}): 2372, 1649, 1590. mp 152–153 °C. HRMS (ESI) m/z : $[\text{M} + \text{H}]^+$ calcd for $\text{C}_{19}\text{H}_{21}\text{N}_4\text{O}_2$ 337.1665, found 337.1676.

General Procedure for the Synthesis of Long-Chained *N*-Phenyl-5-hydroxy-1,2,3-triazoleamides **10b and **10c** (GP6).** To a solution of carboxylic acid **11b** or **11c** (0.40 mmol, 1 equiv) in dry DCM (0.2M) in a round-bottom flask was added triethylamine (0.48 mmol, 1.2 equiv) and aniline (0.48 mmol, 1.2 equiv). The solution was added with carbonyldiimidazole (CDI) (0.48 mmol, 1.2 equiv) and stirred overnight at room temperature. The crude mixture was diluted with AcOEt (20 mL), washed with HCl (5 mL of 0.5 M aq.), dried over sodium sulfate, and evaporated under vacuum. The crude amide was purified by flash column chromatography (AcOEt/petroleum ether 1:1 to 1:0) to yield the title compounds **10b** and **10c** as white solids.

***N*-Phenyl-6-(5-hydroxy-1-phenyl-1,2,3-triazol-4-yl)hexanamide **10b**.** White solid (49 mg, 35% yield). $^1\text{H NMR}$ (400 MHz, DMSO- d_6): δ 11.36 (bs, 1H), 9.86 (s, 1H), 7.71 (d, $J = 6.7$ Hz, 2H), 7.62–7.50 (m, 4H), 7.48–7.40 (m, 1H), 7.32–7.22 (m, 2H), 7.05–6.96 (m, 1H), 2.58 (t, $J = 7.5$ Hz, 2H), 2.31 (t, $J = 7.4$ Hz, 2H), 1.72–1.55 (m, 4H), 1.45–1.33 (m, 2H). $^{13}\text{C}\{^1\text{H}\}$ NMR (101 MHz, DMSO- d_6): δ 171.3, 139.4, 135.9, 129.3, 128.7, 127.9, 122.9, 122.2, 119.0, 36.4, 28.7, 28.4, 25.0, 23.2. IR (KBr, cm^{-1}): 2387, 1654, 1599. mp 148–149.3 °C. HRMS (ESI) m/z : $[\text{M} + \text{H}]^+$ calcd for $\text{C}_{20}\text{H}_{23}\text{N}_4\text{O}_2$ 351.1821, found 351.1815.

***N*-Phenyl-7-(5-hydroxy-1-phenyl-1,2,3-triazol-4-yl)heptanamide **10c**.** White solid (70 mg, 48% yield). $^1\text{H NMR}$ (400 MHz, DMSO- d_6): δ 9.87 (s, 1H), 7.71 (d, $J = 7.8$ Hz, 2H), 7.62–7.49 (m, 4H), 7.48–7.40 (m, 1H), 7.31–7.21 (m, 2H), 7.05–6.96 (m, 1H), 2.57 (t, $J = 7.5$ Hz, 2H), 2.30 (t, $J = 7.4$ Hz, 2H), 1.66–1.55 (m, 4H), 1.41–1.29 (m, 4H). $^{13}\text{C}\{^1\text{H}\}$ NMR (101 MHz, DMSO- d_6): δ 171.3, 139.4, 135.8, 129.3, 128.7, 127.9, 122.9, 122.2, 119.0, 36.4, 28.7, 28.5 (2C), 25.1, 23.3. IR (KBr, cm^{-1}): 2367, 1658, 1535. mp 142–142.6 °C. HRMS (ESI) m/z : $[\text{M} + \text{H}]^+$ calcd for $\text{C}_{21}\text{H}_{25}\text{N}_4\text{O}_2$ 365.1978, found 365.1991

■ ASSOCIATED CONTENT

SI Supporting Information

The Supporting Information is available free of charge at <https://pubs.acs.org/doi/10.1021/acs.joc.1c00778>.

Copies of the ^1H - and $^{13}\text{C}\{^1\text{H}\}$ -NMR spectra of the synthesized compounds, HPLC data of **5a**, potentiometric titration procedure for triazole **5a**, and crystallographic data of **5a** (PDF)

Accession Codes

CCDC 2051417 contains the supplementary crystallographic data for this paper. These data can be obtained free of charge via www.ccdc.cam.ac.uk/data_request/cif, or by emailing data_request@ccdc.cam.ac.uk, or by contacting The Cambridge Crystallographic Data Centre, 12 Union Road, Cambridge CB2 1EZ, UK; fax: +44 1223 336033.

■ AUTHOR INFORMATION

Corresponding Author

Mauro F. A. Adamo – Centre for Synthesis and Chemical Biology (CSCB), Department of Chemistry, Royal College of

Surgeons in Ireland, Dublin 2, Ireland; orcid.org/0000-0001-9072-3648; Phone: (+353) 1 4022208; Email: madamo@rcsi.ie

Authors

Roberta Pacifico – Centre for Synthesis and Chemical Biology (CSCB), Department of Chemistry, Royal College of Surgeons in Ireland, Dublin 2, Ireland

Dario Destro – Centre for Synthesis and Chemical Biology (CSCB), Department of Chemistry, Royal College of Surgeons in Ireland, Dublin 2, Ireland

Malachi W. Gillick-Healy – Centre for Synthesis and Chemical Biology (CSCB), Department of Chemistry, Royal College of Surgeons in Ireland, Dublin 2, Ireland; KelAda Pharmachem Ltd., Belfield, Dublin 4, Ireland

Brian G. Kelly – KelAda Pharmachem Ltd., Belfield, Dublin 4, Ireland

Complete contact information is available at: <https://pubs.acs.org/10.1021/acs.joc.1c00778>

Author Contributions

^VR.P. and D.D. contributed equally.

Notes

The authors declare no competing financial interest.

■ ACKNOWLEDGMENTS

We acknowledge IRC GOIPG/2018/3165 for support to R.P. and IRC EPSPD/2019/184 for a grant to M.G.H.

■ REFERENCES

- (1) Dheer, D.; Singh, V.; Shankar, R. Medicinal Attributes of 1,2,3-Triazoles: Current Developments. *Bioorg. Chem.* **2017**, *71*, 30–54.
- (2) Zurro, M.; Mancheño, O. G. 1,2,3-Triazole-Based Catalysts: From Metal- to Supramolecular Organic Catalysis. *Chem. Rec.* **2017**, *17* (5), 485–498.
- (3) Diaz-Ortiz, A.; Prieto, P.; Carrillo, J. R.; Martin, R.; Torres, I. Applications of Metal-Free 1,2,4-Triazole Derivatives in Materials Science. *Curr. Org. Chem.* **2015**, *19* (7), 568–584.
- (4) Agard, N. J.; Prescher, J. A.; Bertozzi, C. R. A Strain-Promoted [3 + 2] Azide-Alkyne Cycloaddition for Covalent Modification of Biomolecules in Living Systems. *J. Am. Chem. Soc.* **2004**, *126* (46), 15046–15047.
- (5) Doiron, J. E.; Le, C. A.; Ody, B. K.; Brace, J. B.; Post, S. J.; Thacker, N. L.; Hill, H. M.; Breton, G. W.; Mulder, M. J.; Chang, S.; Bridges, T. M.; Tang, L.; Wang, W.; Rowe, S. M.; Aller, S. G.; Turlington, M. Evaluation of 1,2,3-Triazoles as Amide Bioisosteres In Cystic Fibrosis Transmembrane Conductance Regulator Modulators VX-770 and VX-809. *Chem. - Eur. J.* **2019**, *25* (14), 3662–3674.
- (6) Bonandi, E.; Christodoulou, M. S.; Fumagalli, G.; Perdicchia, D.; Rastelli, G.; Passarella, D. The 1,2,3-Triazole Ring as a Bioisostere in Medicinal Chemistry. *Drug Discovery Today* **2017**, *22* (10), 1572–1581.
- (7) Huisgen, R. The Concerted Nature of 1,3-Dipolar Cycloadditions and the Question of Diradical Intermediates. *J. Org. Chem.* **1976**, *41* (3), 403–419.
- (8) Nixon, N. S.; Scheinmann, F.; Suschitzky, J. L. Heterocyclic synthesis with allene-1,3-dicarboxylic esters and acids: New chromone, chromone, quinolone, α -pyrone and coumarin synthesis. *Tetrahedron Lett.* **1983**, *24* (6), 597–600.
- (9) Tornøe, C. W.; Christensen, C.; Meldal, M. Peptidotriazoles on Solid Phase: [1,2,3]-Triazoles by Regiospecific Copper(I)-Catalyzed 1,3-Dipolar Cycloadditions of Terminal Alkynes to Azides. *J. Org. Chem.* **2002**, *67* (9), 3057–3064.
- (10) Rostovtsev, V. V.; Green, L. G.; Fokin, V. V.; Sharpless, K. B. A Stepwise Huisgen Cycloaddition Process: Copper(I)-Catalyzed

Regioselective "Ligation" of Azides and Terminal Alkynes. *Angew. Chem., Int. Ed.* **2002**, *41*, 2596–2599.

(11) Zhang, L.; Chen, X.; Xue, P.; Sun, H. H. Y.; Williams, I. D.; Sharpless, K. B.; Fokin, V. V.; Jia, G. Ruthenium-Catalyzed Cycloaddition of Alkynes and Organic Azides. *J. Am. Chem. Soc.* **2005**, *127*, 15998–15999.

(12) Buckle, B. D. R.; Rockell, C. J. M. Pharmaceuticals-research, B. N-Protecting Group for the Synthesis of N-Unsubstituted v-Triazoles. *J. Chem. Soc., Perkin Trans. 1* **1982**, 627–630.

(13) Swamer, F. W.; Hauser, C. R. Claisen Acylations and Carboethoxylation of Ketones and Esters by Means of Sodium Hydride. *J. Am. Chem. Soc.* **1950**, *72* (3), 1352–1356.

(14) Mao, S.; Chen, K.; Yan, G.; Huang, D. β -Keto Acids in Organic Synthesis. *Eur. J. Org. Chem.* **2020**, 2020 (5), 525–538.

(15) Dimroth, O. Ueber eine Synthese von Derivaten des 1,2,3-Triazols. *Ber. Dtsch. Chem. Ges.* **1902**, *35*, 1029–1038.

(16) Danence, L. J. T.; Gao, Y.; Li, M.; Huang, Y.; Wang, J. Organocatalytic Enamide-Azide Cycloaddition Reactions: Regiospecific Synthesis of 1,4,5-Trisubstituted-1,2,3-Triazoles. *Chem. - Eur. J.* **2011**, *17* (13), 3584–3587.

(17) Destro, D.; Sanchez, S.; Cortigiani, M.; Adamo, M. F. A. Reaction of Azides and Enolisable Aldehydes under the Catalysis of Organic Bases and: Cinchona Based Quaternary Ammonium Salts. *Org. Biomol. Chem.* **2017**, *15* (24), 5227–5235.

(18) Pippione, A. C.; Sainas, S.; Boschi, D.; Lolli, M. L. Hydroxyazoles as Acid Isosteres and Their Drug Design Applications—Part 2: Bicyclic Systems. In *Advances in Heterocyclic Chemistry*, Vol. 134; Elsevier Inc., 2021.

(19) Tao, L.; Han, J.; Tao, F. M. Correlations and Predictions of Carboxylic Acid PKa Values Using Intermolecular Structure and Properties of Hydrogen-Bonded Complexes. *J. Phys. Chem. A* **2008**, *112* (4), 775–782.

(20) Pippione, A. C.; Dosio, F.; Ducime, A.; Federico, A.; Martina, K.; Sainas, S.; Frølund, B.; Gooyit, M.; Janda, K. D.; Boschi, D.; Lolli, M. L. Substituted 4-Hydroxy-1,2,3-Triazoles: Synthesis, Characterization and First Drug Design Applications through Bioisosteric Modulation and Scaffold Hopping Approaches. *MedChemComm* **2015**, *6* (7), 1285–1292.

(21) Ballatore, C.; Huryn, D. M.; Smith, A. B. Carboxylic Acid (Bio)Isosteres in Drug Design. *ChemMedChem* **2013**, *8* (3), 385–395.

(22) Richon, V. M.; Webb, Y.; Merger, R.; Sheppard, T.; Jursic, B.; Ngo, L.; Civoli, F.; Breslow, R.; Rifkind, R. A.; Marks, P. A. Second Generation Hybrid Polar Compounds Are Potent Inducers of Transformed Cell Differentiation. *Proc. Natl. Acad. Sci. U. S. A.* **1996**, *93* (12), 5705–5708.

(23) Richon, V. M.; Emiliani, S.; Verdin, E.; Webb, Y.; Breslow, R.; Rifkind, R. A.; Marks, P. A. A Class of Hybrid Polar Inducers of Transformed Cell Differentiation Inhibits Histone Deacetylases. *Proc. Natl. Acad. Sci. U. S. A.* **1998**, *95* (6), 3003–3007.

(24) Tsatsaroni, A.; Zoidis, G.; Zoumpoulakis, P.; Tsotinis, A.; Taylor, M. C.; Kelly, J. M.; Fytas, G. An E/Z Conformational Behaviour Study on the Trypanocidal Action of Lipophilic Spiro Carbocyclic 2,6-Diketopiperazine-1-Aceto-hydroxamic Acids. *Tetrahedron Lett.* **2013**, *54* (25), 3238–3240.

(25) Marmion, C. J.; Griffith, D.; Nolan, K. B. Hydroxamic Acids - An Intriguing Family of Enzyme Inhibitors and Biomedical Ligands. *Eur. J. Inorg. Chem.* **2004**, 2004 (15), 3003–3016.

(26) Begtrup, M.; Pedersen, C.; Johansson, L.; Nihlgård, B.; Nilsson, L. Reaction of phenyl azide with amides of malonic acids and phenylacetic acid. *Acta Chem. Scand.* **1964**, *18* (6), 1333–1336.

(27) A X-ray crystallographic analysis has been obtained for compound **5a**, and data have been deposited with the Cambridge Crystallographic Data Centre, deposition no. 2051417.

(28) Zhao, Y.; van Nguyen, H.; Male, L.; Craven, P.; Buckley, B. R.; Fossey, J. S. Phosphino-Triazole Ligands for Palladium-Catalyzed Cross-Coupling. *Organometallics* **2018**, *37* (22), 4224–4241.

(29) Paquin, F.; Rivnay, J.; Salleo, A.; Stingelin, N.; Silva-Acuna, C. Multi-Phase Semicrystalline Microstructures Drive Exciton Dissocia-

tion in Neat Plastic Semiconductors. *J. Mater. Chem. C* **2015**, *3* (41), 10715–10722.

(30) Sebest, F.; Lachhani, K.; Pimpasri, C.; Casarrubios, L.; White, A. J. P.; Rzepa, H. S.; Díez-González, S. Cycloaddition Reactions of Azides and Electron-Deficient Alkenes in Deep Eutectic Solvents: Pyrazolines, Aziridines and Other Surprises. *Adv. Synth. Catal.* **2020**, *362*, 1877–1886.

(31) Brito, L.; Kesternich, V.; Pérez-Fehrmann, M.; Aranedo, C.; Cárdenas, A. Crystal structure of ethyl 5-methyl-1-(pyridin-3-yl)-1H-1,2,3-triazole-4-carboxylate, C₁₁H₁₂N₄O₂. *Z. Kristallogr. - New Cryst. Struct.* **2017**, *232* (6), 1011–1012.